ArticlePloS one2025
The disease and economic burden of notified and underestimated Campylobacter enteritis cases and associated sequelae in Germany.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccording to surveillance data, Campylobacter enteritis (CE) has been the most frequently notified bacterial gastrointestinal disease in Germany and Europe for many years. Presumably, the total number of cases is underestimated because an unknown number of cases is not diagnosed and some diagnosed cases are not reported in the surveillance system. The aim of this study was to estimate the disease and economic burden of CE and its related sequelae in Germany.
methodsThe disability-adjusted life years (DALY) as well as the direct and indirect costs associated with the five-year (2018-2022) mean number of CE cases and related sequelae were estimated in a Monte Carlo simulation. The age- and gender-specific characteristics were integrated where possible. The underestimated CE cases were quantified by reconstructing the surveillance pyramid using age group-specific health care seeking parameters.
resultsThe estimated incidence rate was 553 CE cases (95%-CI: 551-555 cases) per 100,000 inhabitants per year. This corresponds to 7.7 underestimated cases per notified case. Underestimation was lowest in the age group <5 years and highest in the age group 15-29 years. The notified plus underestimated CE cases and associated sequelae resulted in a loss of 6,764 DALY (95%-CI: 6,689-6,839 DALY), 88% of which were due to sequelae. The total economic burden amounted to 263.5 million Euros (95%-CI: 262.5-264.4 million Euros). Approximately 25% of the total DALY and costs were attributable to the notified cases.
conclusionsThe results suggest a substantial burden due to CE, both in terms of DALY and costs, in Germany. Especially the high number of underestimated cases and associated sequelae contribute to the health and economic burden - although some remaining uncertainties cannot be ruled out. By using age-specific multipliers to determine the underestimated cases, age-related differences in DALY and cost of illness can be accounted for, thereby preventing an overestimation of the total burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.